These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30314912)

  • 1. The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships.
    Odevall L; Hong D; Digilio L; Sahastrabuddhe S; Mogasale V; Baik Y; Choi S; Kim JH; Lynch J
    Vaccine; 2018 Oct; 36(45):6606-6614. PubMed ID: 30314912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
    Baik YO; Choi SK; Olveda RM; Espos RA; Ligsay AD; Montellano MB; Yeam JS; Yang JS; Park JY; Kim DR; Desai SN; Singh AP; Kim IY; Kim CW; Park SN
    Vaccine; 2015 Nov; 33(46):6360-5. PubMed ID: 26348402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future cholera vaccines.
    Shaikh H; Lynch J; Kim J; Excler JL
    Vaccine; 2020 Feb; 38 Suppl 1():A118-A126. PubMed ID: 31879125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
    Sur D; Lopez AL; Kanungo S; Paisley A; Manna B; Ali M; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Rao R; Nguyen TV; Donner A; Ganguly NK; Nair GB; Bhattacharya SK; Clemens JD
    Lancet; 2009 Nov; 374(9702):1694-702. PubMed ID: 19819004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges for programmatic implementation of killed whole cell oral cholera vaccines for prevention and control of cholera: a meta-opinion.
    Chatterjee P; Kanungo S; Dutta S
    Expert Opin Biol Ther; 2018 Sep; 18(9):983-988. PubMed ID: 30107757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Hillchol®, a low-cost inactivated single strain Hikojima oral cholera vaccine.
    Sharma T; Joshi N; Kumar Mandyal A; Nordqvist SL; Lebens M; Kanchan V; Löfstrand M; Jeverstam F; Mainul Ahasan M; Khan I; Karim M; Muktadir H; Muktadir A; Gill D; Holmgren J
    Vaccine; 2020 Nov; 38(50):7998-8009. PubMed ID: 33139137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The history of OCV in India and barriers remaining to programmatic introduction.
    Mogasale V; Kanungo S; Pati S; Lynch J; Dutta S
    Vaccine; 2020 Feb; 38 Suppl 1():A41-A45. PubMed ID: 31982258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Quantitative Systematic Review and Meta-Analysis of the Effectiveness of Oral Cholera Vaccine as a Reactive Measure in Cholera Outbreaks.
    Schwerdtle P; Onekon CK; Recoche K
    Prehosp Disaster Med; 2018 Feb; 33(1):2-6. PubMed ID: 29317005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving immunization approaches to cholera.
    Saha A; Rosewell A; Hayen A; MacIntyre CR; Qadri F
    Expert Rev Vaccines; 2017 Mar; 16(3):235-248. PubMed ID: 27805467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake during an oral cholera vaccine pilot demonstration program, Odisha, India.
    Kar SK; Pach A; Sah B; Kerketta AS; Patnaik B; Mogasale V; Kim YH; Rath SB; Shin S; Khuntia HK; Bhattachan A; Puri MK; Wierzba TF; Kaljee LM
    Hum Vaccin Immunother; 2014; 10(10):2834-42. PubMed ID: 25483631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case-control study in Lusaka, Zambia.
    Sialubanje C; Kapina M; Chewe O; Matapo BB; Ngomah AM; Gianetti B; Ngosa W; Kasonde M; Musonda K; Mulenga M; Michelo C; Sinyange N; Bobo P; Zyambo K; Mazyanga L; Bakyaita N; Mukonka VM
    BMJ Open; 2022 Nov; 12(11):e066945. PubMed ID: 36368745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings.
    Hsiao A; Desai SN; Mogasale V; Excler JL; Digilio L
    Bull World Health Organ; 2017 Apr; 95(4):303-312. PubMed ID: 28479625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing cholera in India: Synthesizing evidences through a systematic review for policy discussion on the use of oral cholera vaccine.
    Panda S; Chatterjee P; Deb A; Kanungo S; Dutta S
    Vaccine; 2020 Feb; 38 Suppl 1():A148-A156. PubMed ID: 31405636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global oral cholera vaccine use, 2013-2018.
    Pezzoli L;
    Vaccine; 2020 Feb; 38 Suppl 1(Suppl 1):A132-A140. PubMed ID: 31519444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?
    Clemens J; Holmgren J
    Curr Top Microbiol Immunol; 2014; 379():231-58. PubMed ID: 24402712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine.
    Terrinoni M; Nordqvist SL; Löfstrand M; Nilsson F; Källgård S; Sharma T; Lebens MR; Holmgren J
    Vaccine; 2023 May; 41(21):3347-3357. PubMed ID: 37085452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmatic Preparations and challenges for OCV introduction in India.
    Haldar P
    Vaccine; 2020 Feb; 38 Suppl 1():A175-A177. PubMed ID: 31307875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine.
    Jackson SS; Chen WH
    Future Microbiol; 2015; 10(8):1271-81. PubMed ID: 26228388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.
    Desai SN; Pezzoli L; Alberti KP; Martin S; Costa A; Perea W; Legros D
    Hum Vaccin Immunother; 2017 Mar; 13(3):579-587. PubMed ID: 27813703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010-2011.
    Date KA; Vicari A; Hyde TB; Mintz E; Danovaro-Holliday MC; Henry A; Tappero JW; Roels TH; Abrams J; Burkholder BT; Ruiz-Matus C; Andrus J; Dietz V
    Emerg Infect Dis; 2011 Nov; 17(11):2105-12. PubMed ID: 22099114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.